(PRESS RELEASE) BEDFORD, MA - Ocular Therapeutix Inc. (NASDAQ: OCUL) announced the closing of its underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $5 per share.
The shares of common stock issued and sold in the offering at the closing include 975,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price, less underwriting discounts and commissions. The offering was made pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission. All of the shares in the offering were sold by Ocular.
The aggregate net proceeds before expenses to Ocular from the offering are approximately $35.1 million, after deducting underwriting discounts and commissions.
Piper Jaffray & Co. acted as sole manager and underwriter for the offering.
Ocular intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund the planned resubmission of its new drug application for DEXTENZA, to fund the clinical development of OTX-TP, OTX-TIC and OTX-TKI, to fund additional preclinical and regulatory activities for its other product candidates, including through its collaboration with Regeneron, and for working capital and other general corporate purposes and pursuit of its other research and development efforts.
Hear What the Industry Thinks About the Ultimate Lens Package by Essilor
Eye care professionals, patients, and Essilor sales consultants shared their feedback on the Ultimate Lens Package. Watch to see why they believe the innovation behind the lens can make the difference for your practice and for your patients. For more information on the Ultimate Lens Package, contact an Essilor Sales Consultant or click here.